Technology Offers

Therapeutics

Recombinant human transglutaminase 1 encapsulated into liposomes for treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis

On 7 June 2013 orphan designation was granted by the European Commission for recombinant human transglutaminase 1 encapsulated into liposomes for the treatment of transglutaminase 1-deficient autosomal recessive congenital ichthyosis. EMA website

NEWS: a crowdfunding campaign https://www.comitatouffi.org has been set up by Elena Ravano Calheiros, the mother of twin daughters, both affected by the disease.

TG1-Liposomes

 

A novel approach to develop anti-metastatic drugs based on inhibition of Ena/VASP EVH1 domains

Anti-metastatic drugs

 

 

Research Tools / Protein Engineering 

KCNQ4 and KCNQ5 ion channels for the identification of selective channel function modulators  

Ion channels

 

Volume-regulated anion channel VRAC as a target in drug discovery

VRAC

 

Novel TPH inhibitors for the treatment of serotonin-related diseases

TPH inhibitors

 

 

Disease models


ISG15 KO

Useful for studying antiviral responses
Ref: Mol Cell Biol Aug 2005, Vol 25(15) pp 6338-45 by Osiak et al. 

 

USP8 lox/lox
Useful for studying the roles of ubiquitin-dependent protein trafficking of membrane proteins
Ref: Mol Cell Biol Jul 2007, Vol 27, No. 13, pp 5029-39 by Niendorf et al.

 

USP18 knock-in (USP18C61A/C61A)
Useful for studying the therapeutic inhibition of the enzymatic activity of USP18
Ref: Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1577-82 by Ketscher et al.

 

 

Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Germany
+4930 94793 - 100 
+4930 94793 - 109 (Fax)
info(at)fmp-berlin.de

Like many sites, we use cookies to optimize the user's browsing experience. Data Protection OK